Seeking Alpha

FDA Panel: Naproxen not safer than other painkillers

  • An FDA advisory committee has voted 16-9 that there is not enough evidence to assert that the anti-inflammatory painkiller Naproxen, which Bayer (BAYRY) sells as Aleve, is safer for the heart than rival drugs.
  • The vote means that Bayer and other sellers of Naproxen won't have a marketing advantage over other painkillers such as Advil, Ibuprofen and Celebrex.
  • The FDA had organized the meeting after epidemiologists who work at the agency said there was evidence to show that Naproxen is safer.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector